|
Genedrive PLC on Friday said its CYP2C19-ID genetic testing kit has shown superior performance compared to laboratory testing in a recently published clinical study. The Manchester, England-based pharmacogenetic testing company said the study, published in the Journal of Molecular Diagnostics, highlighted the kit’s ability to deliver 100% sensitivity and specificity. It also reported a failure rate of just under 1%, three times lower than laboratory testing. Shares in Genedrive were up 4.5% at 2.38 pence each in London after the results were released on Friday morning. The kit, which uses a simple cheek swab to provide rapid results, identified seven patients with loss-of-function genetic variants that laboratory tests and competing point-of-care platforms would have missed. These variants are particularly prevalent in certain ethnic groups. The CYP2C19-ID kit is designed to guide treatment decisions for patients with ischaemic stroke or transient ischaemic attack. It has already been recommended by the UK National Institute for Health & Care Excellence for prescribing clopidogrel to stroke patients Chief Executive Officer Gino Miele said: ‘With this study evidencing superior performance compared to laboratory testing and by extrapolation our nearest competitor product, we are well positioned to capitalise on the emerging clinical pharmacogenetics area of point of care CYP2C19 genotyped-guided clopidogrel treatment both domestically and internationally.’ Genedrive said the kit provides a non-invasive, cost-effective alternative to standard laboratory testing and expects its use to expand as the demand for pharmacogenetic testing grows. Copyright 2024 Alliance News Ltd. All Rights reserved.
|
